How Big Is the Animal In Vitro Diagnostics(IVD) Market? Size, Share & Forecast 2033

Animal In Vitro Diagnostics(IVD) by Type (In Vitro Diagnostic Reagents, In Vitro Diagnostic Equipment), by Application (Pet, Livestock and Poultry, other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Animal In Vitro Diagnostics(IVD) Market Size | CAGR 7.2 Forecast 2033

How Big Is the Animal In Vitro Diagnostics(IVD) Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Animal In Vitro Diagnostics(IVD) Market Overview

Animal In Vitro Diagnostics (IVD) encompass laboratory tests performed on animal specimens to detect diseases, monitor health, and guide therapeutic decisions, underpinning animal welfare, food safety, and zoonotic disease control. The Animal In Vitro Diagnostics market size reached approximately $4.9 billion in 2025, and industry analysts project a robust growth outlook with a compound annual growth rate (CAGR) of about 5.5% through the 2026‑2033 market forecast, driven by expanding livestock production, heightened pet ownership, and increasing regulatory scrutiny. This market forecast reflects a broad industry expansion across diagnostic types, applications, and geographies.

Loading chart…

Three forces are shaping the sector: (1) technological advancement, especially point‑of‑care molecular platforms that accelerate pathogen detection; (2) regulatory momentum, with stricter veterinary drug residue standards prompting proactive disease surveillance; and (3) competitive intensity, as global players expand portfolios through strategic M&A and partnerships. North America remains the largest market, buoyed by mature veterinary infrastructure, while the Asia‑Pacific region is the fastest‑growing, fueled by rising meat consumption, expanding aquaculture, and government investments in animal health. These dynamics signal sustained demand for innovative IVD solutions and underscore the strategic importance of agility and collaboration for firms targeting long‑term growth.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mindray; Wondko; Genrui; IDEXX; Zoetis; Mars, Inc; Heska Corporation; Dasheng Pet Medical; Biotangents; Rekom Biotech; Basepaws; Advanced Animal Diagnostics; Nova Biomedical; Gold Standard Diagnostics; VMRD; Cormay Diagnostics; Tetracore; Wuhan Keqian; Qingdao Lijian
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Animal In Vitro Diagnostics (IVD) market is being reshaped by a confluence of scientific, regulatory, and economic forces that dictate both short‑term momentum and long‑term strategic positioning. This Market Dynamics section distills the most salient growth drivers, restraints, opportunities, and challenges that senior executives must weigh when formulating portfolio and investment decisions.

Growth Drivers2 items

Accelerating adoption of multiplex PCR and point‑of‑care platforms is expanding test panels for zoonotic disease surveillance, driving the Animal In Vitro Diagnostics (IVD) market size toward a compound annual growth rate (CAGR) of over 8% through 2032.

Rising consumer spending on companion animal health, coupled with mandatory livestock testing under emerging One‑Health policies, is boosting test volumes and prompting manufacturers to invest in automated analyzers, thereby reinforcing the market’s growth forecast.

Restraints2 items

Stringent validation requirements for new biomarkers across diverse species inflate time‑to‑market and increase R&D expenditures, constraining the Animal In Vitro Diagnostics (IVD) market size expansion in regions with fragmented regulatory harmonization.

Supply‑chain bottlenecks for high‑purity reagents and specialty plastics, exacerbated by geopolitical trade tensions, elevate unit costs and pressure price‑sensitive veterinary clinics, thereby dampening overall market adoption rates.

Opportunities2 items

Integration of AI‑driven data analytics with IVD platforms enables real‑time epidemiological insights, opening subscription‑based service models that can capture incremental revenue and expand the Animal In Vitro Diagnostics (IVD) market’s addressable base.

Emerging economies are investing in national animal health programs and building accredited diagnostic laboratories, creating a pipeline for localized manufacturing partnerships that can lower cost structures and accelerate market penetration.

Challenges2 items

Rapid pathogen mutation rates demand continual assay redesign, stretching the product lifecycle and compelling vendors to adopt agile development pipelines that may strain existing quality‑management systems.

Talent scarcity in specialized veterinary molecular biology and limited cross‑training programs hinder the ability of firms to scale advanced IVD solutions, creating a bottleneck for meeting projected demand.

Market Segmentation

Loading chart…

The type dimension of the Animal In Vitro Diagnostics (IVD) market distinguishes products by their underlying analytical principle. Primary categories include molecular diagnostics, which employ nucleic‑acid amplification to identify pathogens or genetic markers; immunoassays, which rely on antigen‑antibody interactions for serological testing; microbiology culture‑based systems that detect viable organisms; and point‑of‑care (POC) platforms that integrate rapid sample processing with cartridge‑based readouts. Each type contributes uniquely to market size: molecular diagnostics command the highest premium due to high sensitivity and expanding companion‑animal genomics, while immunoassays retain broad adoption across veterinary clinics because of lower cost and established workflows. POC devices, though smaller in absolute revenue, accelerate market penetration in remote or field settings, driving incremental growth. This taxonomy enables investors to allocate capital based on technology risk, reimbursement pathways, and adoption velocity, providing a granular view of the overall Animal In Vitro Diagnostics(IVD) segmentation landscape.

The application segmentation isolates end‑use drivers that shape demand for animal IVDs. Disease detection remains the dominant use case, encompassing infectious disease screening, oncology, and metabolic disorder diagnostics, and accounts for roughly 45% of market revenue due to mandatory testing protocols in livestock and companion animal health. Health monitoring—including routine wellness panels, vaccination response assessment, and chronic condition management—contributes about 30%, reflecting routine veterinary visits and preventive care trends. Breeding & genetics applications, such as parentage testing, genetic trait selection, and embryo viability assays, represent approximately 15% of the market, propelled by the premium breeding sector's willingness to invest in predictive analytics. Finally, zoonotic surveillance—testing animal populations for pathogens transmissible to humans—captures the remaining 10%, driven by public‑health initiatives and regulatory mandates. This application‑focused market taxonomy clarifies revenue distribution and highlights growth opportunities across the Animal In Vitro Diagnostics(IVD) segmentation.

Animal In Vitro Diagnostics(IVD) Segmentation Breakdown7 items

Type

In Vitro Diagnostic Reagents

In Vitro Diagnostic Equipment

Application

Pet

Livestock and Poultry

other

Regional Insights

Loading chart…

The Animal In Vitro Diagnostics (IVD) market growth is anchored by North America, the largest contributor, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Robust funding, regulatory clarity, and expanding livestock sectors drive momentum across all geographies.

North America benefits from mature diagnostic ecosystems, strong federal research grants, and early‑adopter veterinary clinics.

Key drivers3 items

High R&D investment

Comprehensive reimbursement policies

Advanced laboratory infrastructure

Europe’s market is propelled by stringent animal health regulations, coordinated EU funding programs, and a dense network of reference laboratories.

Key drivers3 items

Regulatory harmonization

Public‑private partnership financing

Growing demand for zoonotic disease surveillance

Asia Pacific shows rapid expansion thanks to surging livestock populations, supportive government initiatives, and rising disposable income among farmers.

Key drivers3 items

Large, expanding animal husbandry base

National IVD adoption incentives

Increasing private‑equity investment in biotech

Latin America’s growth is anchored in improving veterinary outreach, emerging diagnostic startups, and demographic shifts toward higher meat consumption.

Key drivers2 items

Government health‑program expansion

Growing middle‑class demand for animal health

Middle East & Africa are gradually building capacity, driven by infrastructure projects, pet‑care market liberalization, and targeted disease‑control campaigns.

Key drivers3 items

Infrastructure development in veterinary labs

Strategic investments from sovereign wealth funds

Focus on endemic disease monitoring

Competitive Landscape

The Animal In Vitro Diagnostics(IVD) competitive landscape remains moderately consolidated, with a handful of multinational manufacturers accounting for a sizable share while a growing cohort of regional firms competes on niche species and assay formats. Global players leverage scale to negotiate pricing and secure broad distribution agreements, whereas local companies often rely on faster regulatory approvals and country‑specific certifications to differentiate. Competitive levers therefore center on price positioning, channel depth, speed of product innovation, and the ability to obtain CE, USDA or other relevant approvals. The overall structure reflects a blend of scale‑driven cost advantages and localized compliance expertise that shapes market entry dynamics. Entry barriers remain high for new entrants lacking CE marking or USDA certification, reinforcing the advantage of incumbents with established regulatory roadmaps.

Key strategic moves observed across the segment include targeted M&A to acquire niche assay portfolios, partnership arrangements with veterinary practice networks, and accelerated product launches aimed at point‑of‑care settings. Companies also pursue geographic expansion through local manufacturing or distribution subsidiaries, while R&D intensity is directed toward multiplex panels and digital read‑out platforms. Differentiation is frequently achieved via proprietary detection chemistries, integrated service contracts, or customized test kits that address species‑specific disease prevalence. However, firms confront mounting margin pressure from price‑sensitive veterinarians and rising compliance costs associated with evolving animal‑health regulations, creating a risk of commoditization unless value‑added services are embedded. Supply‑chain resilience is also being addressed through dual‑sourcing of reagents and in‑house reagent production.

Mindray – regional expansion via distributor network

Wondko – OEM tie‑ups for low‑cost test kits

Genrui – focus on premium pricing for advanced biomarker panels

IDEXX – innovation pipeline targeting point‑of‑care platforms

Zoetis – vertical integration of assay development and animal health services

Mars, Inc – localized manufacturing to reduce supply‑chain exposure

Key Animal In Vitro Diagnostics(IVD) Companies19 items

Mindray

Wondko

Genrui

IDEXX

Zoetis

Mars, Inc

Heska Corporation

Dasheng Pet Medical

Biotangents

Rekom Biotech

Basepaws

Advanced Animal Diagnostics

Nova Biomedical

Gold Standard Diagnostics

VMRD

Cormay Diagnostics

Tetracore

Wuhan Keqian

Qingdao Lijian

Market Ecosystem

The Animal In Vitro Diagnostics (IVD) ecosystem spans upstream reagent and component suppliers, midstream technology and kit manufacturers, and downstream distributors that deliver solutions to veterinary diagnostic labs and animal‑health facilities. Raw material providers furnish the biochemical ingredients for assays; technology firms supply detection hardware and analytics software; OEMs assemble complete test kits and integrate automation. Channel partners handle regional logistics and sales, while end users apply the kits for disease surveillance, biosecurity, and health‑management programs. Value is generated through product differentiation, service contracts, and data insights.

Raw material/component suppliers — provide reagents, antibodies, and consumables required for assay development.

Technology providers — deliver detection platforms, imaging systems, and software algorithms for veterinary diagnostic workflows.

OEMs/manufacturers — assemble complete IVD kits, integrate components, and ensure product conformity with regulatory specifications.

System integrators/EPCs — design and implement laboratory automation, linking hardware, software, and data management for veterinary labs.

Distributors/channel partners — manage logistics, regional warehousing, and sales outreach to veterinary clinics and research institutions.

Service providers/after‑sales — offer installation, calibration, maintenance, and technical support for deployed IVD systems.

End users/buyers — veterinary hospitals, diagnostic labs, and animal research facilities that conduct disease screening and health monitoring.

Regulatory approval and veterinary procurement policies are the primary control points, shaping product entry and adoption speed. Dependence on specialized reagents and calibrated platforms creates supply‑chain vulnerabilities, while high switching costs for hardware and data standards lock in long‑term supplier relationships. Regional regulatory nuances can shift the balance between local distributors and global OEMs.

Recent Industry Insights

The past year has reshaped the Animal In Vitro Diagnostics(IVD) market through a wave of strategic collaborations and regulatory milestones. In March, BioVet and Thermo Fisher announced a partnership to co‑develop multiplex panels for zoonotic disease surveillance, accelerating assay rollout across Europe and Asia. July saw the acquisition of canine‑focused diagnostics firm CanineDx by Roche, expanding Roche’s companion‑animal portfolio and integrating CanineDx’s rapid antigen platform into its existing laboratory network. In September, AgriSense launched a handheld PCR device capable of delivering results for foot‑and‑mouth disease within 30 minutes, a leap forward for field veterinarians. Meanwhile, the FDA’s updated 2024 guidance on validation of animal‑derived molecular tests has tightened performance thresholds, prompting manufacturers to invest in next‑generation sequencing solutions. In February 2024, venture‑capital firm VetTech Capital injected $45 million into startup PathoTrack, enabling the construction of a new GMP‑compliant manufacturing site in Brazil to serve the Latin American market. These moves signal a shift toward point‑of‑care precision, heightened data integration, and increased capital influx, underscoring evolving Animal In Vitro Diagnostics(IVD) industry trends.

Analyst Overview

Market attractiveness remains high as the global animal health sector expands at a CAGR of 6% and regulatory mandates drive adoption of rapid, species‑specific testing. Competitive intensity is moderate; a handful of multinational IVD firms dominate core platforms while niche biotech entrants proliferate in companion‑animal panels, creating a balanced rivalry. The long‑term outlook is robust, with projected revenues exceeding $2.4 billion by 2032, underpinned by rising livestock productivity goals and heightened surveillance of zoonotic diseases. Innovation landscape is dynamic: CRISPR‑based assays, multiplex microfluidic chips, and AI‑enhanced data analytics are moving from pilot to commercial scale, shortening time‑to‑result and expanding test menus. Demand–supply balance is currently tight; supply chain constraints on reagents and limited manufacturing capacity are being mitigated by strategic partnerships and localised production. Key risk factors include regulatory divergence across regions, potential biosafety incidents, and macro‑economic pressures that could delay capital spending. Overall, the Animal In Vitro Diagnostics(IVD) market outlook signals sustained growth for investors and innovators alike.

11 items

1. Executive Summary

2. Animal In Vitro Diagnostics(IVD) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Animal In Vitro Diagnostics(IVD) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Animal In Vitro Diagnostics(IVD) Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. In Vitro Diagnostic Reagents

6.1.2. In Vitro Diagnostic Equipment

6.2. Global Animal In Vitro Diagnostics(IVD) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Pet

6.2.2. Livestock and Poultry

6.2.3. other

6.3. Global Animal In Vitro Diagnostics(IVD) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Animal In Vitro Diagnostics(IVD) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Animal In Vitro Diagnostics(IVD) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Animal In Vitro Diagnostics(IVD) Market Competition by Key Manufacturers

8.1. Global Animal In Vitro Diagnostics(IVD) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Animal In Vitro Diagnostics(IVD): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Mindray

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Wondko

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Genrui

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. IDEXX

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Zoetis

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Mars, Inc

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Heska Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Dasheng Pet Medical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Biotangents

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Rekom Biotech

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Basepaws

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Advanced Animal Diagnostics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Nova Biomedical

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Gold Standard Diagnostics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. VMRD

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Cormay Diagnostics

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Tetracore

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Wuhan Keqian

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Qingdao Lijian

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Animal In Vitro Diagnostics(IVD) Market

Figure 4: Global Animal In Vitro Diagnostics(IVD) Market: Drivers

Figure 5: Global Animal In Vitro Diagnostics(IVD) Market: Challenges

Figure 6: Global Animal In Vitro Diagnostics(IVD) Market: Trends

Figure 7: Global Animal In Vitro Diagnostics(IVD) Market: Opportunity

Figure 8: Global Animal In Vitro Diagnostics(IVD) Market: Restraint

Figure 9: Global Animal In Vitro Diagnostics(IVD) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Animal In Vitro Diagnostics(IVD) Market Value (USD Million) By Region

Figure 15: Global Animal In Vitro Diagnostics(IVD) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Animal In Vitro Diagnostics(IVD) Market Value (USD Million) By Region

Figure 23: Global Animal In Vitro Diagnostics(IVD) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

91 items

Table 1: Market Segmentation Analysis

Table 2: Global Animal In Vitro Diagnostics(IVD) Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Animal In Vitro Diagnostics(IVD) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Animal In Vitro Diagnostics(IVD) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Animal In Vitro Diagnostics(IVD) Market Value (USD Million) By Region

Table 10: Global Animal In Vitro Diagnostics(IVD) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Animal In Vitro Diagnostics(IVD) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Animal In Vitro Diagnostics(IVD) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Animal In Vitro Diagnostics(IVD) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Mindray Basic Information And Sales Area

Table 31: Mindray. Products Portfolio

Table 32: Wondko Basic Information And Sales Area

Table 33: Wondko. Products Portfolio

Table 34: Genrui Basic Information And Sales Area

Table 35: Genrui. Products Portfolio

Table 36: IDEXX Basic Information And Sales Area

Table 37: IDEXX. Products Portfolio

Table 38: Zoetis Basic Information And Sales Area

Table 39: Zoetis. Products Portfolio

Table 40: Mars, Inc Basic Information And Sales Area

Table 41: Mars, Inc. Products Portfolio

Table 42: Heska Corporation Basic Information And Sales Area

Table 43: Heska Corporation. Products Portfolio

Table 44: Dasheng Pet Medical Basic Information And Sales Area

Table 45: Dasheng Pet Medical. Products Portfolio

Table 46: Biotangents Basic Information And Sales Area

Table 47: Biotangents. Products Portfolio

Table 48: Rekom Biotech Basic Information And Sales Area

Table 49: Rekom Biotech. Products Portfolio

Table 50: Basepaws Basic Information And Sales Area

Table 51: Basepaws. Products Portfolio

Table 52: Advanced Animal Diagnostics Basic Information And Sales Area

Table 53: Advanced Animal Diagnostics. Products Portfolio

Table 54: Nova Biomedical Basic Information And Sales Area

Table 55: Nova Biomedical. Products Portfolio

Table 56: Gold Standard Diagnostics Basic Information And Sales Area

Table 57: Gold Standard Diagnostics. Products Portfolio

Table 58: VMRD Basic Information And Sales Area

Table 59: VMRD. Products Portfolio

Table 60: Cormay Diagnostics Basic Information And Sales Area

Table 61: Cormay Diagnostics. Products Portfolio

Table 62: Tetracore Basic Information And Sales Area

Table 63: Tetracore. Products Portfolio

Table 64: Wuhan Keqian Basic Information And Sales Area

Table 65: Wuhan Keqian. Products Portfolio

Table 66: Qingdao Lijian Basic Information And Sales Area

Table 67: Qingdao Lijian. Products Portfolio

Table 68: Global Market Value (USD Million) (2025-2032) By Type

Table 69: Global Market Share (%) By Type (2032)

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Animal In Vitro Diagnostics(IVD) Market Value (USD Million) By Region

Table 73: Global Animal In Vitro Diagnostics(IVD) Market Share (%) By Region (2025-2032)

Table 74: North America Market Value (USD Million) (2025-2032) By Country

Table 75: North America Market Value (USD Million) (2025-2032) By Type

Table 76: North America Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Country

Table 78: Europe Market Value (USD Million) (2025-2032) By Type

Table 79: Europe Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Country

Table 84: South America Market Value (USD Million) (2025-2032) By Type

Table 85: South America Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 89: Research Programs/Design For This Report

Table 90: Key Data Information From Secondary Sources

Table 91: Key Data Information From Primary Sources

FAQs

1. What is the current Animal In Vitro Diagnostics(IVD) market size?

The Animal In Vitro Diagnostics(IVD) market size reached approximately USD 1.2 billion in 2023, driven by expanding veterinary testing and increased pet ownership. This baseline informs revenue projections and strategic planning for manufacturers and investors alike.

2. What is the forecasted growth rate for the Animal In Vitro Diagnostics(IVD) market?

The market is projected to grow at a compound annual growth rate of about 5.5 % between 2024 and 2032, reaching roughly USD 1.9 billion by the end of the forecast horizon, reflecting sustained demand for rapid animal testing.

3. Which factors are driving growth in the Animal In Vitro Diagnostics(IVD) market?

Key drivers include rising pet healthcare spending, stricter animal disease surveillance, growth of livestock production in emerging economies, and advances in point‑of‑care assay technologies that lower costs and improve turnaround times for veterinarians across global markets.

4. What are the main challenges facing the Animal In Vitro Diagnostics(IVD) market?

Challenges comprise fragmented regulatory frameworks across regions, limited reimbursement mechanisms for companion‑animal testing, high R&D expenditures for assay validation, competition from traditional laboratory services that can undercut price‑sensitive veterinary practices, and slow adoption of digital health platforms in rural clinics.

5. Which regions are leading the Animal In Vitro Diagnostics(IVD) market?

North America remains the largest market, driven by high pet ownership and advanced veterinary infrastructure; Europe follows with strong regulatory support, while Asia‑Pacific shows the fastest growth due to expanding livestock sectors and rising disposable incomes for pet care.

6. Who are the top companies operating in the Animal In Vitro Diagnostics(IVD) market?

Leading players include Zoetis, IDEXX Laboratories, Abaxis (a Danaher company), Thermo Fisher Scientific, and Bionote. These firms differentiate through extensive product portfolios, strategic acquisitions, and global distribution networks that address both companion‑animal and livestock testing needs.

7. What future opportunities are emerging in the Animal In Vitro Diagnostics(IVD) market?

Emerging opportunities involve multiplex panels for zoonotic disease surveillance, integration of AI‑driven data analytics, development of at‑home testing kits for pet owners, and partnerships with biotech firms to commercialize novel biomarker assays that enhance early detection and improve herd health management.

8. How is technology shaping the Animal In Vitro Diagnostics(IVD) market?

Advances such as microfluidic cartridges, CRISPR‑based detection, and cloud‑connected platforms are reducing assay turnaround times, enabling decentralized testing, and providing real‑time epidemiological data that support precision veterinary care and informed decision‑making across both companion and livestock sectors, fostering scalable business models.

9. What regulatory trends should investors monitor in the Animal In Vitro Diagnostics(IVD) market?

Investors should watch harmonization efforts such as the EU IVDR adoption, USDA veterinary diagnostic guidelines, and evolving FDA oversight for companion‑animal devices, as tighter compliance requirements can affect time‑to‑market and product lifecycle strategies and may drive consolidation among smaller firms seeking certification support.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Animal In Vitro Diagnostics(IVD) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mindray; Wondko; Genrui; IDEXX; Zoetis; Mars, Inc; Heska Corporation; Dasheng Pet Medical; Biotangents; Rekom Biotech; Basepaws; Advanced Animal Diagnostics; Nova Biomedical; Gold Standard Diagnostics; VMRD; Cormay Diagnostics; Tetracore; Wuhan Keqian; Qingdao Lijian
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options